Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Phase 2 Recruiting 400 enrolled Dendreon Talosix · collab WCG IRB · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

A multicenter, open-label, prospective study to investigate immune boost response changes in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Timeline

Start: 2023-10-02
Primary completion: 2031-12-31
Completion: 2032-06-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sipuleucel-T	Cell therapy	—	Intravenous

Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T

Summary

Timeline

Drugs

Indications